Deans' stroke musings: Combination of flupentixol and melitracen tablets and rTMS improves post-stroke depression through neurovegetative symptoms changes: a retrospective analysis

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, May 25, 2026

Combination of flupentixol and melitracen tablets and rTMS improves post-stroke depression through neurovegetative symptoms changes: a retrospective analysis

Preventing depression by having EXACT 100% RECOVERY PROTOCOLS makes much more sense that after the fact treatment! And your stroke medical 'professionals' are too stupid to understand that!

Combination of flupentixol and melitracen tablets and rTMS improves post-stroke depression through neurovegetative symptoms changes: a retrospective analysis

Haizhou Wang 1,2
K
Kejun Zhang 3
Z
Zikui Yang 3
Zhaokai Wang 3
Y
Yanbo Cheng 1*

1. Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
2. First Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China

Abstract

Background:

Post-stroke depression (PSD) is one of the most common neuropsychiatric complications among stroke survivors, with a substantial impact on functional recovery and quality of life. This study aimed to investigate the effect of flupentixol and melitracen tablets combined with repetitive transcranial magnetic stimulation (rTMS) on patients with post-stroke depression (PSD) and analyze the differences in the key factors of the 17-item Hamilton Depression Scale (HAMD₁₇) scores.

Methods:

We conducted a retrospective analysis of 121 patients with PSD, including 57 patients who used the flupentixol and melitracen tablets alone and 64 patients who additionally received rTMS. General information was assessed. Follow-up indices after treatment included P300, National Institutes of Health Stroke Scale (NIHSS), HAMD₁₇, and the Barthel Index (BI) and Pittsburgh Sleep Quality Index (PSQI) questionnaire. Observable mood (OM), cognitive symptoms (CS) and neurovegetative symptoms (NS), the three dimensions of HAMD₁₇ was also analyzed. The concentrations of 5-hydroxytryptamine (5-HT), norepinephrine (NE), neuropeptide Y (NPY) and brain-derived neurotrophic factor (BDNF) in the serum were measured during all time points.

Results:

There was significant difference in the amplitude and latency of P300 and NS after 2 weeks and 4 weeks treatment between the groups, while there was significant difference in the concentrations of 5-HT, NE, NPY, BDNF and the scores of NIHSS, HAMD₁₇, BI, PSQI after 4 weeks treatment. The treatment outcomes at 4 weeks demonstrated statistically significant differences compared to those observed at 2 weeks both at control group and combination group. The results also indicated that the treatment in the combined group demonstrated superiority over that in the control group with respect to both onset time and therapeutic efficacy.

Conclusion:

Combination of flupentixol and melitracen tablets and rTMS could significantly improve the depressive symptoms of patients with PSD, NS was the symptom dimension most closely related to the therapeutic response. More importantly, the P300 parameter might provide an early and objective indicator of the neurophysiological changes associated with the treatment.